ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.23	2.83	4.89	9.46	7.23
Cash & Short-Term Investments	3.23	2.83	4.89	9.46	7.23
Cash Growth	13.96%	-42.04%	-48.33%	30.91%	17.06%
Inventory	-	-	-	1.28	0.59
Prepaid Expenses	0.2	0.2	0.49	1.35	0.39
Total Current Assets	3.43	3.03	5.38	12.09	8.21
Property, Plant & Equipment	0.65	0.47	0.74	0.77	0.55
Other Long-Term Assets	0.37	3.26	3.15	0.01	0.01
Total Assets	4.45	6.75	9.27	12.87	8.76
Accounts Payable	0.27	0.36	0.61	0.79	0.4
Accrued Expenses	0.07	0.19	0.75	0.5	0.42
Short-Term Debt	0.17	0.15	0.16	0.12	0.08
Current Portion of Long-Term Debt	-	0.03	0.03	-	-
Current Portion of Leases	0.1	0.17	0.15	0.13	0.08
Total Current Liabilities	0.61	0.9	1.7	1.54	0.99
Long-Term Debt	-	-	-	0.03	0.34
Long-Term Leases	0.49	0.19	0.37	0.52	0.27
Other Long-Term Liabilities	0.8	-	-	-	-
Total Liabilities	1.89	1.1	2.07	2.09	1.6
Common Stock	0	0	0	0	0
Additional Paid-In Capital	106	97.58	89.07	79.46	64.49
Retained Earnings	-103.44	-91.93	-81.87	-68.69	-57.34
Comprehensive Income & Other	-	0.01	0.01	0.01	0.01
Total Common Equity	2.56	5.66	7.2	10.78	7.17
Shareholders' Equity	2.56	5.66	7.2	10.78	7.17
Total Liabilities & Equity	4.45	6.75	9.27	12.87	8.76
Total Debt	0.75	0.54	0.71	0.8	0.77
Net Cash (Debt)	2.48	2.29	4.18	8.67	6.46
Net Cash Growth	8.06%	-45.25%	-51.72%	34.18%	18.64%
Net Cash Per Share	12.25	-	-	-	-
Filing Date Shares Outstanding	0.56	-	-	-	-
Total Common Shares Outstanding	0.54	-	-	-	-
Working Capital	2.83	2.13	3.68	10.55	7.22
Book Value Per Share	4.77	-	-	-	-
Tangible Book Value	2.56	5.66	7.2	10.78	7.17
Tangible Book Value Per Share	4.77	-	-	-	-

Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q